Article Text

AB0790 Clinical characteristics, treatment patterns and disease control among patients with systemic lupus erythematosus receiving steroid-containing standard care regimens in germany, france and spain.
  1. S. Narayanan1,
  2. A. Baskett2,
  3. Y. Lu2,
  4. R. Hutchings2,
  5. V. Koscielny3
  1. 1Ipsos Healthcare, Columbia, United States
  2. 2Ipsos Healthcare
  3. 3GlaxoSmithKline, London, United Kingdom


Background Corticosteroids (CCS) are a cornerstone of current treatment regimens in Systemic Lupus Erythematosus (SLE). However, increasing evidence points to their significant contribution to medium-to-long term organ damage.

Objectives To assess the clinical characteristics, treatment patterns and disease control among patients with SLE receiving steroid-containing standard care (SC) regimen in Germany (DE), France (FR) and Spain (SP).

Methods A multi-center medical chart review study of SLE patients (16-89 yrs) was conducted in August-September 2012 among rheumatologists and internal medicine physicians in hospital and private practices. Physicians were screened for practice length (3-35 yrs) and SLE patient volume (≥15 SLE patients/month) and recruited from a geographically representative sample in each country. Medical charts of eligible patients (approx. 5 per center/practice) with relapse-remitting or persistently active SLE and currently treated as part of usual care were randomly selected. Physicians abstracted de-identified data on diagnosis, disease manifestations & treatment patterns. Physicians reported whether patient’s SLE disease was under control with current treatment (yes/no; per physician-perception). We report data for patients treated with CCS-containing SC regimens.

Results Analysis included 339 eligible SLE patients (DE:118, FR:125, SP:96); mean age: 40.1yrs, female: 81%; Caucasian: 89%. The most frequent organ systems affected by SLE were: musculoskeletal (86%), mucocutaneous (82%), heamatologic (58%), renal (30%) and pulmonary (17%). Patient disease status/control and treatment patterns are shown in the table.

Conclusions SLE patients in diverse healthcare settings in 3 European countries had significant residual disease burden during treatment with CCS containing regimens. Majority of patients had moderate/severe disease, and less than one-third were reported to have disease not under control. Differences in CCS dosage appear to exist across the countries studied, with 33% - 58% of the patients on CCS>7.5mg/day despite multi-drug regimens.

Disclosure of Interest None Declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.